An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haas, Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haas

Abstract

Background: Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia.

Methods: This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone treatment. The risperidone dose was flexible and ranged from 2 to 6 mg/day. Most subjects enrolled for 6 months; a subset enrolled for 12 months. Assessment tools included the Positive and Negative Syndrome Scale total and factor scores, Clinical Global Impressions, Children's Global Assessment Scale, adverse event (AE) monitoring, vital signs, laboratory testing, and extrapyramidal symptom rating scales.

Results: A total of 390 subjects were enrolled; 48 subjects had received placebo in a previous double-blind study; 292 subjects had received risperidone as part of their participation in one of two previous controlled studies; and 50 subjects were enrolled directly for this study. A total of 279 subjects enrolled for 6 months of treatment, and 111 subjects enrolled for 12 months of treatment. Overall, 264 (67.7%) subjects completed this study: 209 of the 279 subjects (75%) in the 6-month group and 55 of the 111 subjects (50%) in the 12-month group. The median mode dose was 3.8 mg/day. At 6 months, all three groups experienced improvement from open-label baseline in symptoms of schizophrenia as well as general assessments of global functioning. Improvements were generally maintained for the duration of treatment. The most common AEs (≥10% of subjects) were somnolence, headache, weight increase, hypertonia, insomnia, tremor, and psychosis. Potentially prolactin-related AEs (PPAEs) were reported by 36 (9%) subjects. The AE profile in this study was qualitatively similar to those of other studies in adult subjects with schizophrenia and in other psychiatric studies of risperidone in pediatric populations.

Conclusions: Risperidone maintenance treatment in adolescents over 6 to 12 months was well tolerated, consistent with related studies in this clinical population, and associated with continued efficacy.

Clinical trials: ClinicalTrials.gov registration number: NCT00246285 https://ichgcp.net/clinical-trials-registry/NCT00246285?term=NCT00246285&rank=1.

Figures

Figure 1
Figure 1
Study scheme and overall disposition
Figure 2
Figure 2
Positive and Negative Syndrome Scale (PANSS) total score over time (observed cases). Data are presented as mean (SD). Data are presented for all subjects to the 6- or 12-month end point. The RIS/RIS 6- and 12-month groups are mutually exclusive
Figure 3
Figure 3
Percentage of subjects with improved, the same, or worsened clinical status at the 6-month end point, by Clinical Global Impressions of Severity ratings. Intent-to-treat population, last observation carried forward
Figure 4
Figure 4
Mean change inzscores for body weight (A) and body mass index (B) over the course of the study for the PBO/RIS group, RIS/RIS group, and all subjects. Data are presented for all subjects to the 6- or 12-month end point. The RIS/RIS 6- and 12-month groups are mutually exclusive

References

    1. Asarnow JR, Tompson MC, Goldstein MJ. Childhood-onset schizophrenia: a followup study. Schizophr Bull. 1994;20:599–617.
    1. Remschmidt H, Theisen FM. Schizophrenia and related disorders in children and adolescents. J Neural Transm Suppl. 2005. pp. 121–141.
    1. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull. 1994;20:727–745.
    1. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res. 2007;95:1–8. doi: 10.1016/j.schres.2007.06.004.
    1. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S. et al.A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432–1441. doi: 10.1176/appi.ajp.2008.07061035.
    1. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S. et al.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60–71.
    1. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L. et al.Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–1431. doi: 10.1176/appi.ajp.2008.08050756.
    1. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J. et al.Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194:158–164. doi: 10.1192/bjp.bp.107.046177.
    1. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19:611–621. doi: 10.1089/cap.2008.0144.
    1. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R. et al.Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547–1556. doi: 10.1176/appi.ajp.2007.06111932.
    1. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70:247–258. doi: 10.4088/JCP.08m03538.
    1. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771–791. doi: 10.1097/01.chi.0000220851.94392.30.
    1. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20:195–201. doi: 10.1080/09540260801889179.
    1. Correll CU. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. J. Clin Psych. 2011;72(1):e01. doi: 10.4088/JCP.9101tx6c.
    1. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol. 2008;18:337–345. doi: 10.1089/cap.2007.0098.
    1. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16:379–392. doi: 10.1089/cap.2006.16.379.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538–546. doi: 10.4088/JCP.v58n1205.
    1. Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. 1976. pp. 218–222.
    1. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H. et al.A children's global assessment scale (CGAS) Arch Gen Psychiatry. 1983;40:1228–1231. doi: 10.1001/archpsyc.1983.01790100074010.
    1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–303. doi: 10.1136/adc.44.235.291.
    1. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13–23. doi: 10.1136/adc.45.239.13.
    1. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976. Abnormal involuntary movement scale; pp. 534–537.
    1. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19.
    1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676. doi: 10.1192/bjp.154.5.672.
    1. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty TK, Gangadhar BN. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin Neuropharmacol. 2010;33:288–292. doi: 10.1097/WNF.0b013e3181fa2a6f.
    1. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD. et al.Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci. 2008;23:685–690. doi: 10.3346/jkms.2008.23.4.685.
    1. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol. 2002;22:424–426. doi: 10.1097/00004714-200208000-00015.
    1. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res. 2003;60:99–100.
    1. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28:213–218.
    1. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J. et al.Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992;85:295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x.
    1. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–835.
    1. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW. et al.A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25–40.
    1. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166:712–726. doi: 10.1192/bjp.166.6.712.
    1. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002;110:e34. doi: 10.1542/peds.110.3.e34.
    1. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161:677–684. doi: 10.1176/appi.ajp.161.4.677.
    1. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163:402–410. doi: 10.1176/appi.ajp.163.3.402.
    1. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol. 2006;16:260–272. doi: 10.1089/cap.2006.16.260.
    1. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry. 2006;15:97–104. doi: 10.1007/s00787-006-0504-0.
    1. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2001;40:4S–23S. doi: 10.1097/00004583-200107001-00002.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit